Affiliation:
1. Urology Department CHU de Pointe‐à‐Pitre, Service d'Urologie Pointe‐à‐Pitre France
2. Urology Department, CHU de Pointe‐à‐Pitre, Univ Antilles, Univ Rennes, Inserm, EHESP Irset (Institut de Recherche en Santé, Environnement et Travail) Pointe‐à‐Pitre France
Abstract
AbstractIntroductionEarly salvage radiotherapy is indicated for patients with biochemical recurrence after radical prostatectomy. However, for various reasons, certain patients do not benefit from this treatment (OBS) or only at a late stage (LSR). There are few studies on this subject and none on a “high‐risk” population, such as patients of African descent. Our objective was to estimate the metastasis‐free (MFS) and overall survival (OS) of patients who did not receive salvage radiotherapy, and to identify risk factors of disease progression.Patients and MethodsThis was a single‐center retrospective study that included 154 patients, 99 in the OBS group and 55 in the LSR group. All were treated by total prostatectomy for localized prostate cancer between January 2000 and December 2020 and none received early salvage radiotherapy after biochemical recurrence.ResultsBaseline characteristics were similar between groups, except for the time to biochemical recurrence. The median follow‐up was 10.0 and 11.8 years for the OBS and LSR groups, respectively. The median time from surgery to LSR was 5.1 years. The two groups did not show a significant difference in MFS: 90.6% at 10 years for the OBS group and 93.3% for the LSR group. The median MFS was 19.8 and 19.6 years for the OBS and LSR groups respectively. OS for the OBS group was significantly higher than that for the LSR group (HR: 2.14 [1.07–4.29]; p = 0.03), with 10‐year OS of 95.9% for the OBS group and 76.1% for the LSR group. Median OS was 16 and 15.6 years for the OBS and LSR groups, respectively.ConclusionIn this study, we observed satisfactory metastasis‐free and OS rates relative to those reported in the scientific literature. The challenge is not to question the benefit of early salvage radiotherapy, but to improve the identification of patients at risk of progression through the development of molecular and genomic tests for more highly personalized medicine.